Insider Trades38 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Sell | GNLX | Yong Yu | Chief Scientific Officer | 653 | $2.94 | $112.7M | -70.83% | +8.73% | $1.9K | -0.24% | — | — |
| Aug 4, 2026 | Sell | GNLX | Joseph Cappello | Chief Technical Officer | 653 | $2.95 | $112.7M | -70.83% | +8.73% | $1.9K | -0.20% | — | — |
| Aug 4, 2026 | Sell | GNLX | Thomas Zindrick | President and CEO | 3,023 | $2.95 | $112.7M | -70.83% | +8.73% | $8.9K | -0.24% | — | — |
| Jun 3, 2026 | Sell | GNLX | Ralph Smalling | Head of Regulatory | 192 | $2.93 | $112.7M | -70.83% | +8.73% | $562.56 | -0.28% | — | — |
| May 11, 2026 | Sell | GNLX | Ralph Smalling | Head of Regulatory | 270 | $2.98 | $112.7M | -70.83% | +8.73% | $804.492 | -0.40% | — | — |
| May 11, 2026 | Sell | GNLX | Yong Yu | Chief Scientific Officer | 605 | $2.97 | $112.7M | -70.83% | +8.73% | $1.8K | -0.40% | — | — |
| May 11, 2026 | Sell | GNLX | Joseph Cappello | Chief Technical Officer | 605 | $2.97 | $112.7M | -70.83% | +8.73% | $1.8K | -0.39% | — | — |
| May 11, 2026 | Sell | GNLX | Thomas Zindrick | President and CEO | 2,798 | $2.94 | $112.7M | -70.83% | +8.73% | $8.2K | -0.52% | — | — |
| Mar 24, 2026 | Sell | GNLX | Ralph Smalling | Head of Regulatory | 585 | $2.46 | $112.7M | -70.83% | +8.73% | $1.4K | -0.43% | — | — |
| Mar 24, 2026 | Sell | GNLX | Yong Yu | SVP, Clinical Development | 906 | $2.42 | $112.7M | -70.83% | +8.73% | $2.2K | -0.62% | — | — |
| Mar 24, 2026 | Sell | GNLX | Joseph Cappello | Chief Technical Officer | 906 | $2.42 | $112.7M | -70.83% | +8.73% | $2.2K | -0.58% | — | — |
| Mar 24, 2026 | Sell | GNLX | Thomas Zindrick | President and CEO | 3,582 | $2.42 | $112.7M | -70.83% | +8.73% | $8.7K | -0.67% | — | — |
| Aug 21, 2025 | Sell | GNLX | Ralph Smalling | Head of Regulatory | 2,332 | $3.75 | $112.7M | -70.83% | +8.73% | $8.7K | -0.84% | — | — |
| Aug 21, 2025 | Sell | GNLX | Joseph Cappello | Chief Technical Officer | 3,706 | $3.88 | $112.7M | -70.83% | +8.73% | $14.4K | -0.78% | — | — |
| Aug 21, 2025 | Sell | GNLX | Yong Yu | SVP, Clinical Development | 4,192 | $3.82 | $112.7M | -70.83% | +8.73% | $16.0K | -1.41% | — | — |
| Aug 21, 2025 | Sell | GNLX | Thomas Zindrick | President and CEO | 17,182 | $3.86 | $112.7M | -70.83% | +8.73% | $66.4K | -1.56% | — | — |
| May 12, 2025 | Sell | GNLX | Ralph Smalling | Head of Regulatory | 1,259 | $2.92 | $112.7M | -70.83% | +8.73% | $3.7K | -3.50% | — | — |
| May 12, 2025 | Sell | GNLX | Sean Ryder | General Counsel | 4,475 | $2.92 | $112.7M | -70.83% | +8.73% | $13.1K | -8.59% | — | — |
| May 12, 2025 | Sell | GNLX | Joseph Cappello | VP, Pharmaceutical Development | 4,737 | $2.92 | $112.7M | -70.83% | +8.73% | $13.8K | -8.31% | — | — |
| May 12, 2025 | Sell | GNLX | Yong Yu | VP, Clinical Trial Operations | 5,579 | $2.92 | $112.7M | -70.83% | +8.73% | $16.3K | -10.48% | — | — |
| May 12, 2025 | Sell | GNLX | Thomas Zindrick | President and CEO | 10,764 | $2.92 | $112.7M | -70.83% | +8.73% | $31.4K | -5.32% | — | — |
| Dec 16, 2024 | Sell | GNLX | Lourie S. Zak | Chief Financial Officer | 2,103 | $2.34 | $112.7M | -70.83% | +8.73% | $4.9K | -4.90% | — | — |
| Dec 16, 2024 | Sell | GNLX | Ralph Smalling | Head of Regulatory | 2,510 | $2.34 | $112.7M | -70.83% | +8.73% | $5.9K | -13.33% | — | — |
| Dec 16, 2024 | Sell | GNLX | Joseph Cappello | VP, Pharmaceutical Development | 6,300 | $2.34 | $112.7M | -70.83% | +8.73% | $14.7K | -30.07% | — | — |
| Dec 16, 2024 | Sell | GNLX | Thomas Zindrick | President and CEO | 14,315 | $2.34 | $112.7M | -70.83% | +8.73% | $33.5K | -27.70% | — | — |
| Jun 24, 2024 | Sell | GNLX | Caroline Jewett | Head of Quality | 4,961 | $2.12 | $112.7M | -70.83% | +8.73% | $10.5K | -23.47% | — | — |
| Jun 24, 2024 | Sell | GNLX | Sean Ryder | General Counsel | 5,496 | $2.12 | $112.7M | -70.83% | +8.73% | $11.7K | -22.09% | — | — |
| Jun 24, 2024 | Sell | GNLX | Yong Yu | VP, Clinical Trial Operations | 6,849 | $2.12 | $112.7M | -70.83% | +8.73% | $14.5K | -38.66% | — | — |
| Dec 15, 2023 | Sell | GNLX | Yong Yu | VP, Clinical Trial Operations | 32,535 | $13.16 | $112.7M | -70.83% | +8.73% | $428.2K | -84.86% | — | — |
| Dec 7, 2023 | Sell | GNLX | Yong Yu | VP, Clinical Trial Operations | 36,800 | $11.85 | $112.7M | -70.83% | +8.73% | $436.0K | -53.08% | — | — |
| Nov 21, 2023 | Sell | GNLX | Yong Yu | VP, Clinical Trial Operations | 18,665 | $10.26 | $112.7M | -70.83% | +8.73% | $191.6K | -21.21% | — | — |
| Nov 17, 2023 | Sell | GNLX | Yong Yu | VP, Clinical Trial Operations | 18,135 | $11.60 | $112.7M | -70.83% | +8.73% | $210.4K | -8.69% | — | — |
| Oct 24, 2023 | Sell | GNLX | Yong Yu | VP, Clinical Trial Operations | 10,400 | $12.55 | $112.7M | -70.83% | +8.73% | $130.6K | +0.00% | 10b5-1 | — |
| Oct 10, 2023 | Sell | GNLX | Yong Yu | VP, Clinical Trial Operations | 10,400 | $14.01 | $112.7M | -70.83% | +8.73% | $145.7K | +0.00% | 10b5-1 | — |
| Sep 26, 2023 | Sell | GNLX | Yong Yu | VP, Clinical Trial Operations | 10,400 | $14.78 | $112.7M | -70.83% | +8.73% | $153.7K | +0.00% | 10b5-1 | — |
| Sep 20, 2023 | Sell | GNLX | Yong Yu | VP, Clinical Trial Operations | 12,000 | $16.98 | $112.7M | -70.83% | +8.73% | $203.8K | +0.00% | 10b5-1 | — |
| Sep 20, 2023 | Sell | GNLX | Sean Ryder | General Counsel | 20,000 | $18.00 | $112.7M | -70.83% | +8.73% | $360.0K | +0.00% | 10b5-1 | — |
| Sep 15, 2023 | Sell | GNLX | Yong Yu | VP, Clinical Trial Operations | 20,800 | $13.94 | $112.7M | -70.83% | +8.73% | $290.0K | +0.00% | 10b5-1 | — |